Our clinical pipeline

A growing multispecific pipeline spanning neurology, oncology, rare disease and cell therapy.

Program
Indication
Description
Stage
IMX39
Multiple sclerosis
Lead multispecific biologic
Co-developed with the Baker Heart and Diabetes Institute Scheduled for human clinical trials
IMX101
Small cell lung cancer
Multispecific antibody
Preclinical
IMX113
Gaucher’s disease
Enhanced enzyme therapy
Preclinical
IMX114
Cell therapy
Imunexin ™ -enhanced mesenchymal stem cell therapies
Partnered with Mesoblast Ltd
IMX39
Indication
Multiple sclerosis
Description
Lead multispecific biologic
Stage
Co-developed with the Baker Heart and Diabetes Institute Scheduled for human clinical trials
IMX101
Indication
Small cell lung cancer
Description
Multispecific antibody
Stage
Preclinical
Discovery Preclinical Clinical
IMX113
Indication
Gaucher’s disease
Description
Enhanced enzyme therapy
Stage
Preclinical
Discovery Preclinical Clinical
IMX114
Indication
Cell therapy
Description
Imunexin ™-enhanced mesenchymal stem cell therapies
Stage
Partnered with Mesoblast Ltd
Discovery Preclinical Partnered